[Frontiers in Bioscience 1, e15-25 March 1, 1996]
Reprints
PubMed
CAVEAT LECTOR



PHARMACOLOGICAL MANIPULATION OF THE COMPLEMENT SYSTEM IN HUMAN DISEASES.

Syed Shafi Asghar, Ph.D.

Division of Biochemistry and Immunology, Department of Dermatology, Academisch Medisch Centrum, University of Amsterdam, Amsterdam, The Netherlands

Received 12/08/95; Accepted 26/01/96; On-line 03/01/96

5. CONCLUDING REMARKS

High molecular weight natural inhibitors of complement have found clinical use in many diseases but may also prove useful in other complement-mediated diseases. The most promising of these are C1-INH, intravenous immunoglobulin and sCR1. These appear to be non-toxic and non-immunogenic. Complete inhibition of complement by these molecules appears to have little effect, if any, on susceptibility to infection.

In addition to these molecules, membrane inhibitors of complement may also find their way into the clinic. It is hoped that in future, organs of transgenic pigs expressing high levels of multiple human membrane regulators of complement may prove to be useful for transplantation into humans. It is apparent from this review that it is possible to control complement mediated human diseases by use of high molecular weight complement inhibitors of human origin.

[Table of Contents] [Next Section] [Previous Section]